Lipka A, Soland T, Nieminen A, Sapkota D, Haug T, Galtung H
Front Mol Biosci. 2025; 12:1492282.
PMID: 40062228
PMC: 11885147.
DOI: 10.3389/fmolb.2025.1492282.
Meng Y, Deng J, Deng W, Sun Z
Cancer Biol Med. 2025; 22(2).
PMID: 39969204
PMC: 11899592.
DOI: 10.20892/j.issn.2095-3941.2024.0311.
Naei V, Tubelleza R, Monkman J, Sadeghirad H, Donovan M, Blick T
J Transl Med. 2025; 23(1):177.
PMID: 39939997
PMC: 11818323.
DOI: 10.1186/s12967-025-06186-y.
Oriakhi K, Erharuyi O, Orumwensodia K, Essien E, Falodun A, Uadia P
Toxicol Rep. 2024; 13:101833.
PMID: 39717850
PMC: 11665704.
DOI: 10.1016/j.toxrep.2024.101833.
Zhang X, Yang F, Dong C, Li B, Zhang S, Jiao X
J Cell Mol Med. 2024; 28(22):e70166.
PMID: 39580787
PMC: 11586053.
DOI: 10.1111/jcmm.70166.
Correlation between clinicopathological indices and expression of cluster of differentiation 24 and cluster of differentiation 44 biomarkers in oral epithelial dysplasia and oral squamous cell carcinoma patients: A follow-up study.
Ghazi N, Saghravanian N, Anvari K, Mirhashemi M, Erfanian M
Dent Res J (Isfahan). 2024; 21:50.
PMID: 39376260
PMC: 11457982.
FAP Serves as a Prognostic Biomarker in Head and Neck Squamous Cell Carcinoma.
Liao Z, Fan H, Weng J, Zhou J, Zheng Y
Anal Cell Pathol (Amst). 2024; 2024:8810804.
PMID: 38826849
PMC: 11142855.
DOI: 10.1155/2024/8810804.
FRZB: a potential prognostic marker for head and neck squamous cell carcinoma.
Li Y, Gu F, Huang X, Huang W, Xiang J, Yue J
Braz J Med Biol Res. 2024; 57:e13368.
PMID: 38775547
PMC: 11101165.
DOI: 10.1590/1414-431X2024e13368.
Identification of protein methyltransferases 5 associated with ferroptosis and immune cell infiltration of head and neck squamous cell carcinoma.
Zhang X, Liu Q, Wang L, Peng Q
Aging (Albany NY). 2024; 16(8):7426-7436.
PMID: 38663941
PMC: 11087109.
DOI: 10.18632/aging.205768.
Integrative analysis revealed a correlation of PIAS family genes expression with prognosis, immunomodulation and chemotherapy.
Zhang Q, Zhang J, Lan T, He J, Lei B, Wang H
Eur J Med Res. 2024; 29(1):195.
PMID: 38528630
PMC: 10962104.
DOI: 10.1186/s40001-024-01795-7.
CELSR3 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment.
Wu Z, Zhu Z, Wu W, Hu S, Cao J, Huang X
Eur Arch Otorhinolaryngol. 2024; 281(6):3143-3156.
PMID: 38507078
PMC: 11065926.
DOI: 10.1007/s00405-024-08566-4.
Engineering models of head and neck and oral cancers on-a-chip.
da Costa Sousa M, Vignolo S, Franca C, Mereness J, Alves Fraga M, Silva-Sousa A
Biomicrofluidics. 2024; 18(2):021502.
PMID: 38464668
PMC: 10919958.
DOI: 10.1063/5.0186722.
Exploring the frontiers: tumor immune microenvironment and immunotherapy in head and neck squamous cell carcinoma.
Liu S, Wang R, Fang J
Discov Oncol. 2024; 15(1):22.
PMID: 38294629
PMC: 10830966.
DOI: 10.1007/s12672-024-00870-z.
The Role of SOX2 and SOX9 in Radioresistance and Tumor Recurrence.
Barbosa S, Laureano N, Wijaya Hadiwikarta W, Visioli F, Bonrouhi M, Pajdzik K
Cancers (Basel). 2024; 16(2).
PMID: 38275880
PMC: 10814462.
DOI: 10.3390/cancers16020439.
Role of Microenvironmental Components in Head and Neck Squamous Cell Carcinoma.
Jumaniyazova E, Lokhonina A, Dzhalilova D, Kosyreva A, Fatkhudinov T
J Pers Med. 2023; 13(11).
PMID: 38003931
PMC: 10672525.
DOI: 10.3390/jpm13111616.
Inhibition of UFM1 expression suppresses cancer progression and is linked to the dismal prognosis and immune infiltration in oral squamous cell carcinoma.
Ke D, Guo H, Jiang N, Shi R, Fan T
Aging (Albany NY). 2023; 15(22):13059-13076.
PMID: 37980168
PMC: 10713408.
DOI: 10.18632/aging.205219.
Expanding the role of combined immunochemotherapy and immunoradiotherapy in the management of head and neck cancer (Review).
Wei C, Lan X, Qiu M, Cui R, Fu Q, Shinge S
Oncol Lett. 2023; 26(3):372.
PMID: 37965160
PMC: 10641411.
DOI: 10.3892/ol.2023.13958.
Overexpression of XRCC1 is Associated with Poor Survival in Patients with Head and Neck Squamous Carcinoma and Has Potential to Be Used as Targeted Therapy by Synthetic Lethality.
Ahirwar S, Lasunte S, Gupta M, Chowdhary R, Kotnis A
Asian Pac J Cancer Prev. 2023; 24(10):3525-3535.
PMID: 37898859
PMC: 10770691.
DOI: 10.31557/APJCP.2023.24.10.3525.
Role of tissue markers associated with tumor microenvironment in the progression and immune suppression of oral squamous cell carcinoma.
Ramalingam S, Shantha S, Muralitharan S, Sudhakar U, Thamizhchelvan H, Parvathi V
Med Oncol. 2023; 40(10):303.
PMID: 37731058
DOI: 10.1007/s12032-023-02169-5.
SLA2 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment.
Wu Z, You C, Zhu Z, Wu W, Cao J, Xie Q
Eur Arch Otorhinolaryngol. 2023; 281(1):427-440.
PMID: 37688682
PMC: 10764518.
DOI: 10.1007/s00405-023-08213-4.